4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) and Siga Technologies (NASDAQ:SIGA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.
Valuation & Earnings
This table compares 4D Molecular Therapeutics and Siga Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 4D Molecular Therapeutics | $40,000.00 | 13,539.81 | -$160.87 million | ($3.75) | -2.53 |
| Siga Technologies | $138.72 million | 3.50 | $59.21 million | $1.02 | 6.65 |
Volatility & Risk
4D Molecular Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for 4D Molecular Therapeutics and Siga Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 4D Molecular Therapeutics | 1 | 1 | 8 | 0 | 2.70 |
| Siga Technologies | 1 | 0 | 0 | 0 | 1.00 |
4D Molecular Therapeutics presently has a consensus price target of $33.25, indicating a potential upside of 250.74%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe 4D Molecular Therapeutics is more favorable than Siga Technologies.
Insider & Institutional Ownership
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 2.0% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares 4D Molecular Therapeutics and Siga Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 4D Molecular Therapeutics | -174,314.17% | -47.27% | -42.39% |
| Siga Technologies | 43.22% | 35.23% | 31.06% |
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
